KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShort-Term Debt repayments
Ratios

BeOne Medicines (ONC) Short-Term Debt repayments (2020 - 2025)

BeOne Medicines (ONC) has disclosed Short-Term Debt repayments for 6 consecutive years, with $102.9 million as the latest value for Q2 2025.

  • On a quarterly basis, Short-Term Debt repayments fell 34.69% to $102.9 million in Q2 2025 year-over-year; TTM through Sep 2025 was $275.8 million, a 10.31% decrease, with the full-year FY2023 number at $309.6 million, up 25.1% from a year prior.
  • Short-Term Debt repayments was $102.9 million for Q2 2025 at BeOne Medicines, down from $172.9 million in the prior quarter.
  • In the past five years, Short-Term Debt repayments ranged from a high of $205.2 million in Q4 2021 to a low of $16.0 million in Q2 2021.
  • A 5-year average of $88.3 million and a median of $83.1 million in 2022 define the central range for Short-Term Debt repayments.
  • Peak YoY movement for Short-Term Debt repayments: surged 1575.76% in 2021, then plummeted 60.78% in 2023.
  • BeOne Medicines' Short-Term Debt repayments stood at $205.2 million in 2021, then crashed by 50.28% to $102.0 million in 2022, then surged by 47.01% to $150.0 million in 2023, then rose by 4.99% to $157.5 million in 2024, then tumbled by 34.69% to $102.9 million in 2025.
  • Per Business Quant, the three most recent readings for ONC's Short-Term Debt repayments are $102.9 million (Q2 2025), $172.9 million (Q1 2025), and $157.5 million (Q2 2024).